Incidence of type 2 diabetes in familial combined hyperlipidemia
| Autor: | Britt Heidemann, Nynke Simons, Jim Luijten, Sophie ten Doeschate, Shadana van Heertum, Nicolaas C. Schaper, Martijn C. G. J. Brouwers, Jacqueline de Graaf, Douwe de Boer, Steven J.R. Meex, Marleen M.J. van Greevenbroek, Coen D.A. Stehouwer |
|---|---|
| Přispěvatelé: | Interne Geneeskunde, MUMC+: MA Endocrinologie (9), RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, Biochemie, MUMC+: DA CDL Algemeen (9), RS: Carim - B01 Blood proteins & engineering, RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: HVC Pieken Maastricht Studie (9), MUMC+: MA Interne Geneeskunde (3), MUMC+: Centrum voor Chronische Zieken (3), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Maag Darm Lever (9), MUMC+: MA Hematologie (9), MUMC+: MA Medische Oncologie (9), MUMC+: MA Nefrologie (9), MUMC+: MA Reumatologie (9) |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Cardiovascular and Metabolic Risk STATIN THERAPY LIVER Endocrinology Diabetes and Metabolism Population Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Hyperlipidemia Familial Combined 030209 endocrinology & metabolism Hyperlipidemias Type 2 diabetes Gastroenterology GLUCOSE 03 medical and health sciences MELLITUS 0302 clinical medicine Insulin resistance Internal medicine Diabetes mellitus insulin resistance Hyperlipidemia medicine Humans hyperlipidemia CORONARY-HEART-DISEASE 030212 general & internal medicine education RISK education.field_of_study INSULIN-RESISTANCE business.industry Incidence (epidemiology) Incidence Fatty liver liver fat medicine.disease BODY-FAT DISTRIBUTION Fatty Liver Diabetes Mellitus Type 2 DENSITY-LIPOPROTEIN CHOLESTEROL Cohort epidemiology business FOLLOW-UP |
| Zdroj: | BMJ Open Diabetes Research & Care, 8 BMJ Open Diabetes Research & Care, 8, 1 BMJ Open Diabetes Research & Care, 8(1):001107. BMJ Publishing Group BMJ Open Diabetes Research & Care |
| ISSN: | 2052-4897 |
| Popis: | ObjectiveFamilial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes (T2D) in a longitudinal cohort of FCHL pedigrees.Research design and methodsFCHL patients, their unaffected relatives and spouses included in our baseline cohort in 1998–2005 (n=596) were re-invited to determine the incidence of self-reported T2D (that was confirmed by medical records), used as the primary outcome measure. The Fatty Liver Index (FLI) and Homeostasis Model Assessment Insulin Resistance (HOMA2-IR) were used as markers of fatty liver and insulin resistance, respectively. A subset of the original cohort underwent ultrasound of the liver, and subcutaneous and visceral fat in 2002–2005 (n=275; ‘ultrasound subcohort’).ResultsFollow-up data (median: 15 years) was acquired for 76%. The incidence rate of T2D was significantly higher in FCHL patients compared with spouses (19.2 per 1000 person-years vs 2.8 per 1000 person-years; HR : 6.3, 95% CI: 2.4 to 16.8), whereas no differences were observed between unaffected relatives and spouses (HR: 0.9, 95% CI: 0.3 to 2.6). Cox’s proportional hazard regression analyses showed that baseline HOMA2-IR and FLI≥60, but not waist circumference, BMI, or the FCHL affected state, were independently associated with incident T2D. Similar results were obtained in the ultrasound subcohort (median follow-up: 11 years), in which baseline HOMA2-IR and fatty liver (assessed by ultrasound) were independently associated with incident T2D.ConclusionThis study further corroborates the suggestion that the liver plays a central role in the pathogenesis of cardiometabolic complications in FCHL. It supports periodical screening for T2D in this high-risk population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|